News 2022

Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, and OBI-3424

Title: A phase 3, randomized, open-label study of the anti-Globo H vaccine Adagloxad Simolenin/OBI-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer. Poster / Abstract number: …

OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth

Poster Presentations to highlight the ongoing clinical studies targeting Globo H and AKR1C3 OBI Pharma, Inc. (TPEx: 4174), a leader in First-in-Class Cancer therapeutics, today announced that data highlighting ongoing …

Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science

Title: OBI-3424, an AKR1C3-activated prodrug, exhibits in vivo synergistic anti-tumor effect in combination with pembrolizumab by induction of immunogenic cell death Poster number: 6111 / Abstract number: 2922 Title: High …

OBI Pharma Announces Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science

Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 small molecule  pro-drug) and emerging Globo H science. OBI Pharma, Inc. (TPEx: 4174) today announced scientific data highlighting the antitumor …

OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau

OBI is eligible to receive up to US$ 200 million in total milestone payments and tiered double-digit royalties on net sales. OBI Pharma, Inc. (OBI), a Taiwan biopharma company (TPEx: 4174), and …

OBI Pharma Announces Its In-house COVID-19 Vaccine, BCVax, can induce potent antibodies to neutralize against all variants

OBI Pharma Inc. (TPEx: 4174) announced today research results in the past six-months of their new COVID-19 Vaccine. The vaccine, named BCVax, has been proven to induce potent antibodies against …